BJDX - Bluejay Forward Price-to-Revenue Multiple

The forward P/S of Bluejay Diagnostics (BJDX) correlates with the commercial rollout of the Symphony platform for rapid sepsis diagnostics and FDA approval, while 28.50 determines this parameter level. Current efficiency is constrained by high engineering costs, which necessitate a sharp increase in orders. Growth is based on the integration of portable systems into intensive care and emergency departments of US hospitals.

Bluejay Diagnostics, Inc. - BJDX Market Cap to Future Revenue Ratio (period 08/01/2022 - 09/02/2023)

Metric breakdowns and analytics for Bluejay Diagnostics Corp (BJDX)

- market price and analyst price targets:

Price Chart Bluejay Diagnostics, Inc.|BJDX - Price Target Chart

- market capitalization statistics:

Market Valuation Bluejay Diagnostics Corp|BJDX - Enterprise Value

- business book valuation details:

Book Value per Share Bluejay Diagnostics|BJDX - Total Stockholders' Equity|Market Value to Book Value Ratio bluejaydx.com|BJDX - Aggregate Business Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

BJDX - Net Financial Result|Projected Future Earnings Bluejay Diagnostics|BJDX - P/E Multiple|Forward P/E Multiple Bluejay|BJDX - Price to Net Income Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bluejay Diagnostics Corp|BJDX - Operating profit before amortization|Earnings per share for the last twelve months Bluejay Diagnostics|BJDX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months bluejaydx.com|BJDX - Expected net earnings per share growth this year|Expected earnings per share growth for next year Bluejay Diagnostics

- revenue and sales details:

BJDX - Company Total Sales|Projected Sales Volume Bluejay Diagnostics, Inc.|BJDX - Price-to-Revenue Coefficient|Forward P/S Multiple Bluejay Diagnostics Corp

Initial company analysis:Bluejay Diagnostics, Inc. (BJDX)

Bluejay Diagnostics (BJDX) maintains a strong position in rapid sepsis diagnostics thanks to the Symphony platform, although growth rates are constrained by FDA bureaucracy. By analyzing the business's forward P/S, an investor can see the ratio of current market capitalization to expected revenue, which allows for an assessment of the degree of market optimism and the risk of the asset being overbought as the multiple expands relative to the company's fundamental value.

Key competitors

Price-to-Projected Revenue Ratio Agilent A|Quest Diagnostics Inc. - Price-to-Projected Revenue Ratio|ILMN: Forward Price-to-Revenue Multiple|EXAS - Forward P/S Multiple|RVTY: Forward P/S Multiple|Market Cap to Future Revenue Ratio bio-rad.com (BIO)|Price-to-Projected Revenue Ratio Anbio|SHC (Sotera Health Corp) - Price to Expected Revenue Ratio|Forward P/S Multiple QDEL|Forward P/S Multiple OPKO Health Corp. (OPK)|CareDx, Inc - Forward Price-to-Revenue Multiple|maravai.com (MRVI) - Market Cap to Future Revenue Ratio|FLGT: Forward Price-to-Revenue Multiple|Forward Price to Sales LAB (Standard BioTools Inc)|CTKB: Forward P/S Multiple|Market Cap to Projected Revenue OSUR|XGN (Exagen Inc) - Forward P/S Multiple|mdxhealth.com (MDXH) - Market Cap to Expected Sales Ratio|Forward P/S Multiple LUCD|Forward P/S Multiple prenetics.com (PRE)|Forward P/S Multiple IMDX (Insight Molecular Diagnostics Inc)|Projected Price to Revenue Trinity Biotech PLC|PRPH - Price-to-Projected Revenue Ratio|AIMD (ainos.com) - Market Cap to Projected Revenue|Co-Diagnostics (CODX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Heart Test Laboratories, Inc. (HSCS)|Price-to-Projected Revenue Ratio Biomerica, Inc|Cardio Diagnostics Holdings, Inc. (CDIO) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple ONCO (Onconetix, Inc.)|Price to Expected Revenue Ratio VRAX|Forward P/S Multiple AWH (Aspira Women's Health Inc.)|Market Cap to Expected Sales Ratio Accelerate Diagnostics Inc. (AXDX)|centogene.com - Forward P/S Multiple|Enzo Biochem, Inc. (ENZ) - Forward Price-to-Revenue Multiple|fresh2.co (FRES) - Price-to-Projected Revenue Ratio|GENE - Market Cap to Expected Sales Ratio|ME (23andMe) - Forward P/S Multiple|Price-to-Projected Revenue Ratio PMD